Page 1

Lantheus FIND FIGHT > FOLLOW ™ Lantheus Holdings , Inc. Reports Third Quarter 2021 Financial Results November 4 , 2021 • Worldwide revenue of $ 102.1 million for the third quarter 2021 , representing an increase of 15.3 % from the prior year period • GAAP net loss of $ 13.4 million for the third quarter 2021 , compared to GAAP net loss of $ 6.4 million in the prior year period • GAAP fully diluted net loss of $ 0.20 for the third quarter 2021 , compared to GAAP fully diluted net loss of $ 0.10 in the prior year period ; adjusted fully diluted EPS of $ 0.08 for the third quarter 2021 , compared to adjusted fully diluted EPS of $ 0.04 in the prior year period • Net cash provided by operating activities was $ 4.3 million for the third quarter 2021. Free cash flow was $ 1.9 million in the third quarter 2021 • The Company reported that , following an interim analysis of the ongoing ARROW Phase 2 study of 1095 , a PSMA - targeted therapeutic , in metastatic castration resistant prostate cancer patients , the Independent Data Monitoring Committee recommended the study continue without modifications • The Company provides fourth quarter 2021 revenue and adjusted diluted earnings per share guidance ; increases full year guidance NORTH BILLERICA , Mass . , Nov. 04 , 2021 ( GLOBE NEWSWIRE ) -- Lantheus Holdings , Inc. ( NASDAQ : LNTH ) ( Lantheus ) , an established leader and fully integrated provider committed to innovative imaging diagnostics , targeted therapeutics and artificial intelligence solutions to find , fight and follow serious medical conditions , today reported financial results for its third quarter ended September 30 , 2021 . The Company's worldwide revenue for the third quarter of 2021 totaled $ 102.1 million , compared with $ 88.5 million for the third quarter of 2020 , representing an increase of 15.3 % from the prior year period . The Company's third quarter 2021 GAAP net loss was $ 13.4 million , or $ 0.20 per fully diluted share , as compared to GAAP net loss of $ 6.4 million , or $ 0.10 per fully diluted share for the third quarter of 2020 . The Company's third quarter 2021 adjusted fully diluted earnings per share were $ 0.08 , as compared to $ 0.04 for the third quarter of 2020 , representing an increase of 127.4 % from the prior year period . Lastly , net cash provided by operating activities was $ 4.3 million for the third quarter 2021. Free Cash Flow was $ 1.9 million in the third quarter of 2021 , representing a decrease of approximately $ 2.9 million from the prior year period . " We delivered a strong quarter , with revenue up 15 % year - over - year , highlighted by the robust adoption of PYLARIFY , the first and only commercially available PSMA PET imaging agent , " said Mary Anne Heino , President and CEO . " Although COVID - 19 continued to impact some aspects of our business , we were able to grow our three largest products - DEFINITY , TechneLite and PYLARIFY . We look forward to driving sustainable growth across our portfolio of diagnostic and therapeutic solutions as we find , fight and follow diseases to deliver better patient outcomes . " " We are pleased with the first full quarter of PYLARIFY sales and continue to invest in our commercial launch , including in manufacturing capacity , to meet the increasing demand for this game changing product . We completed the build - out of our commercial infrastructure , which represents the industry's largest PSMA PET - dedicated sales and market access teams , " said Paul Blanchfield , Chief Commercial Officer . " We remain focused on fostering customer adoption and expanding our geographic and market access coverage in service of our customers and the U.S. Prostate Cancer community . " Outlook The Company updates its guidance for full year 2021 and offers the following guidance for the fourth quarter . Q4 FY 2021 Revenue Q4 FY 2021 Adjusted Diluted EPS FY 2021 Revenue FY 2021 Adjusted Diluted EPS Q4 Guidance Issued November 4 , 2021 $ 110 million - $ 115 million $ 0.15 - $ 0.18 FY Guidance Updated November 4 , 2021 $ 405 million - $ 410 million $ 0.40 - $ 0.43 Previous Guidance Issued July 28 , 2021 N / A N / A FY Guidance Issued July 28 , 2021 $ 395 million - $ 402 million $ 0.38 - $ 0.42 On a forward - looking basis , the Company does not provide GAAP income per common share guidance or a reconciliation of adjusted fully diluted EPS